Optimal T cell activation requires the interactions of co-stimulatory molecules, such as those in the CD28 and B7 protein families. Recently, we described the co-stimulatory properties of the murine ligand to ICOS, which we designated as B7RP-1. Here, we report the co-stimulation of human T cells through the human B7RP-1 and ICOS interaction. This ligand-receptor pair interacts with a K D~3 3 nM and an off-rate with a t 1/2 Ͼ 10 min.
Introduction
The interaction of co-stimulatory proteins is required for an antibodies to B7-1 or B7-2, repress disease progression in many spontaneous or experimentally induced animal models optimal response of T cells stimulated by MHC-peptide complexes expressed on antigen-presenting cells (APC). The of autoimmunity (4) . Several in vivo experiments have indicated that aspects of most extensively characterized co-stimulatory pathway is mediated by CD28 and CTLA-4 on T cells (1) . CD28 and T cell function are independent of CD28 regulation. Mice either lacking CD28, both B7-1 and B7-2, or expressing a CTLA-4 interact with the B7 proteins (CD80 and CD86) on either professional or non-professional APC (2, 3) . CD28 is soluble CTLA-4-Ig protein show reduced T h cell activity and class switching; however, many other T cell functions remain considered to be a positive regulator and CTLA-4 a negative regulator of this signaling pathway. T cell activation in the intact (9, 10) . Allografts transplanted into CD28 knockout mice or mice treated with CTLA-4-Ig demonstrate prolonged absence of CD28 co-stimulation leads to anergy, a state of antigen-specific T cell non-responsiveness (4). These and survival (11) ; however, the grafts are eventually rejected. Therefore, co-stimulation mediated through the CD28/B7 pathother properties of CD28 regulation make co-stimulatory proteins attractive therapeutic targets. For example, it has way cannot account for all of the T cell effector functions. Additional T cell co-stimulatory proteins have been identibeen shown that activators of this pathway, such as inhibitory antibodies to the negative regulator CTLA-4 (5) or B7 ligands fied. For example, OX40, 4-1BB and B7-H1 have been shown to co-stimulate T cells (12, 13) . These co-stimulatory proteins (6) (7) (8) , enhance cytolytic T lymphocyte (CTL) responsiveness and anti-tumor immunity. Conversely, inhibitors of CD28 reguhave functions similar to, but not completely overlapping with, CD28. Recently, ICOS was described as an inducible CD28-lation, such as soluble CTLA-4-Ig protein or neutralizing related molecule with co-stimulatory functions on human non-fused human Fc fragment, hFc, contains the C-terminal T cells in vitro (14) . Human ICOS is the ortholog of murine 235 amino acids of human IgG1. hB7RP-1-Fc, hICOS-Fc, CRP-1 (CD28-related protein-1). We recently defined B7RP-1 hFc and DR4-Fc proteins were purified by Protein G-or (B7-related protein-1) as the ligand to murine ICOS, and Protein A-affinity chromatography. demonstrated that B7RP-1 has both in vivo and in vitro costimulatory functions (15) . Here we describe the cloning and Biacore 2000 analysis characterization of human B7RP-1, and demonstrate its coMolecular interactions were analyzed by surface plasmon stimulatory functions through ICOS.
resonance utilizing a Biacore 2000 (Biacore, Uppsala, Sweden). For each experiment, the protein was immobilized onto the dextran layer of CM5 sensor chips via random amine Methods coupling chemistry. The dextran surface was activated with Full-length cloning of human B7RP-1 NHS/EDC and then the proteins, in 10 mM sodium acetate buffer, pH 4.5, at 1 µg/ml, were injected. Proteins were A GenBank blast homology search (GCG, University of Wisexposed to the activated surface until~50-100 response consin) using the murine B7RP-1 sequence (15) retrieved a units (RU) were observed. The remaining active groups on clone (AB014553) containing a 4358 bp sequence with a the dextran were inactivated with ethanolamine. Activated 1679 bp open reading frame. PCR cloning primers were and blocked dextran was generated as a reference surface. designed according to this sequence, and a DNA fragment
In order to determine kinetic values for the interactions of 1313 bp was obtained by 5Ј and 3Ј RACE using Human described, CM5 chip surfaces were immobilized with counterLymph Node Marathon-Ready cDNA (Clontech, Palo Alto, analytes at very low densities (Ͻ250 RU) to omit possible CA). The DNA fragment was used to probe a cDNA library from mass transport effects within the flow cell of the instrument. normal human circulating peripheral blood (PB) lymphocytes.
Furthermore, association and dissociation rates were deterThe DNA fragment (125 ng) was labeled with [ 32 P]dCTP mined globally, i.e. as dependent variables within the full (Amersham, Piscataway, NJ) following the Redi-Prime 2 sensogram data set. This type of data analysis is more robust (Amersham) random prime labeling system protocol. The than an independent analysis of the on and off rates of the colony lift filters were then allowed to hybridize with the probe interaction. Although not analyzed directly, the sensogram at 42°C in the following buffer overnight: 50% formamide, data that were obtained indicated a mono-dispersed sample 5ϫSSPE, 2ϫDenhardt's solution, 0.5% SDS and 100 mg/ml at all analyte concentrations analyzed, based on the data's single-stranded DNA. The sp. act. of the probe was 2.38ϫ10 9 convergence with a theoretical 1:1 interaction. Proteins were c.p.m./µg DNA, in~2 ng labeled probe/ml hybridization buffer. diluted in 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA The filters were then successively washed in 2ϫSSC, 0.1% and 0.005% Tween 20 to nanomolar concentrations, and were SDS at room temperature for 15 min, followed by 1ϫSSC/ injected across the immobilized surfaces at 50 µl/min for 1 0.1% SDS at 55°C for 15 min and 1ϫSSC/0.1% SDS at 60°C min. Double referencing was employed to obtain subtracted for 10 min. The filters were wrapped in plastic and exposed data, utilizing the signals from the reference flow cell and to autoradiography film overnight at -80°C. Three independent buffer alone injections (17). Subtracted data were analyzed clone colonies were chosen, and the DNA was isolated and using the BIAevaluation software Version 3.0 (Biacore). sequenced for each clone in triplicate.
The full-length coding region for human B7RP-1 was inserted in the DNA vector pDSRα and stably transfected into Generation of monocyte-derived DC CHO cells as previously described (15) . Expression of human Peripheral blood mononuclear cells (PBMC) were obtained B7RP-1 was verified using FACS analysis with the human or from random, normal donors by leukophoresis or by venimouse ICOS-Fc protein.
puncture and collection into heparin-coated tubes. DC were grown from adherent PBMC as previously described, except Construction of Fc proteins that human recombinant granulocyte macrophage colony A DNA fragment encoding the human B7RP-1 extracellular stimulating factor, IL-4 and tumor necrosis factor (TNF)-α domain amino acids 1-246 ( Fig. 1 ) was fused in-frame (Amgen Inc., Thousand Oaks, CA) were added at 100 ng/ml upstream of DNA encoding the C-terminal 235 amino acids in EX VIVO serum-free media (Amgen Inc.) on day 0 (18). of human IgG1 in the pDSRα vector. A DNA fragment encoding Loosely adherent and non-adherent cells were harvested on the human ICOS-1 extracellular domain amino acids 1-146 day 7. (14,15) was fused in-frame upstream of DNA encoding the C-terminal 235 amino acids of human IgG1 in the pDSRα PBMC preparation vector. The DNAs were stably transfected into CHO cells as PBMC from healthy donors were isolated by Ficoll-Paque previously described (15) . A DNA fragment encoding the (Sigma) centrifugation, and the cells were washed twice. B DR4 extracellular domain amino acids 1-239 (16) was fused cells and monocytes were purified using mAb-labeled magin frame upstream of human IgG1 in a modified pCEP4 vector netic beads (Miltenyi Biotec, Auburn, CA). Cells were stimu-(Invitrogen, Carlsbad, CA). The resultant DR4-Fc/pCEP4 lated with either 25 µg/ml of lipopolysaccharide (LPS)/dextran plasmid was transfected into 293-EBNA-1 cells using lipofecor 200 ng/ml TNF-α in RPMI 1640 medium containing 10% tamine (Gibco, Gaithersberg, MD) and transfected cells were FCS, PSG, non-essential amino acids, sodium pyruvate, selected with 100 µg/ml hygromycin. Drug-resistant clones were pooled and cultured in serum-free media for 72 h. The HEPES and 2-mercaptoethanol. Table 1 . Biacore analysis of receptor-ligand binding affinities. biotinylated ICOS-Fc (ICOS-Fc-biotin) was used at 10-20 µg/ml and specific binding was detected using SA-PE at 1 µg/ml. Identical concentrations of biotinylated hFc (hFc-
biotin) and SA-PE were used as non-specific binding controls. human Fc-biotin fusion proteins at the described concentraThe antigen-specific mAb anti-HLA-DR-FITC, anti-HLA-DRtions for 30 min. The cells were washed once and SA-PE was phycoerythrin (PE), anti-CD19-FITC, anti-CD80-PE (BD added to the human Fc-biotin fusion protein stained cells for PharMingen, San Diego, CA), anti-CD1a-FITC, anti-CD3-30 min. The stained cells were washed twice and then fixed FITC, anti-CD11c-PE, anti-CD14-FITC, anti-CD14-PE and in 1% formaldehyde. Data were acquired on a FACStation anti-CD86-PE (BD PharMingen), and matched isotype concalibrated with CaliBRITE beads and were analyzed using trols mIgG2a-FITC, mIgG1-FITC and mIgG1-PE (Becton the CellQuest software (BD Pharmingen). The change in mean Dickinson) were used at the concentrations recommended florescence intensity (∆MFI) of ICOS-Fc-biotin binding as by the respective manufacturers. To detect ICOS expression compared to Fc controls was calculated for TNF-α or LPS on T cells, biotinylated human B7RP-1-Fc protein (B7RP-1-treated and untreated cells. DC data were acquired using Fc-biotin) was used at 10 µg/ml. Specific binding was the following settings: detected using streptavidin (SA)-PE (BD PharMingen) at 1 Detector Voltage Amp gain Mode µg/ml. Human T cells (Ͼ98% CD3 ϩ ) were isolated by negative selection of fresh or thawed, adherence depleted PBMC using FSC E-1 6.8 lin mAb-labeled magnetic beads (Miltenyi Biotec), and were SSC 340 1.0 lin activated with phorbol myristate acetate (5 ng/ml) and ionomy-FL1 499 1.0 log FL2 524 1.0 log cin (250 ng/ml) overnight. To detect B7RP-1 expression, DC cultures were gated by FSC and SSC (Ͼ98% HLA-DR ϩ / CD11c ϩ DC) for analysis of DC phenotypes. Student's t-test was used to determine the statistical difference between ∆MFI for TNF-α or LPS treated and untreated cells. P Ͻ 0.05 was Human PB CD14 ϩ monocytes were purified by magnetic bead considered significant. selection, and were preincubated with 50 µg/ml polyclonal hIgG1 and various concentrations (0, 1, 10, 50 and 100 µg/ml, as indicated)
In vitro T cell co-stimulation assays
of either ICOS-Fc (A) or the control Fc construct DR4-Fc (B). Cells were then stained with 10 µg/ml ICOS-Fc-biotin. Staining with a Highly purified human T cells (Ͼ98% CD3 ϩ ) were isolated by human Fc-biotin isotype control (control) was used as background negative selection of fresh or thawed, adherence depleted staining. Secondary staining with SA-PE and construction of Fc fusion PBMC using mAb-labeled magnetic beads (Miltenyi Biotec). B7RP-1-Fc co-stimulation, various concentrations of anti-CD3 (BD PharMingen) and 10 µg/ml anti-human IgG Fc (Sigma) in 100 µl 1ϫPBS were pre-coated onto U-bottom plates by an incubation at 4°C overnight. The unbound anti-CD3 and and 25 ng/ml anti-CD28 or various concentrations of anti-CD28 and 12.5 ng/ml B7RP-1-Fc. To evaluate the contribution anti-human IgG Fc were removed and the cells were cultured in the presence or absence of various concentrations of of IL-2 for B7RP-1-induced growth, 3 µg/ml anti-IL-2 or isotypematched control mAb (BD PharMingen) were added on day B7RP-1-Fc, OPG-Fc control or anti-CD28 (BD PharMingen). 
Results are shown as the mean ∆MFI Ϯ SD from either three (DC and B cell data) or four (monocyte data) normal donors. Student's ttest was used to determine the statistical difference between ∆MFI for TNF-α or LPS treated and untreated cells. P Ͻ 0.05 was considered significant.
a ∆MFI was calculated as follows: MFI of ICOS-Fc-biotin binding minus MFI of Fc controls.
b DC were cultured from human PBMC with or without 100 ng/ml TNF-α and FACS stained as described in Methods. Results were generated from DC gated by FSC and SSC (Ͼ99% HLA-DR hi / CD11c hi DC).
c B cells and monocytes were isolated from human PBMC and cultured up to 24 h in the presence or absence of 200 ng/ml TNF-α or 25 µg/ml LPS/dextran as described in Methods. 
Cytokine production assays
The cytokine assays were conducted on the cell culture supernatants of cells under T cell proliferation conditions Results expression (n ϭ 3, P Ͻ 0.02) as compared to TNF-α untreated DC (left column). In contrast, TNF-α treatment significantly reduced
Cloning of the full-length human B7RP-1 gene
B7RP-1 expression (n ϭ 3, P Ͻ 0.02) on both CD1a ϩ and CD1a -DC.
A homology search using the mouse B7RP-1 sequence (15) identified a putative human clone (AB014553) in a public database. Sequences from this clone were used to isolate a full-length version of the human B7RP-1 gene from a human and 216. These cysteine residues are presumably involved in disulfide bonds that form Ig homology loops. PBL library. The alignment of the human and mouse B7RP-1 proteins is shown in Fig. 1 s -1 and a dissociation rate (k d ) of 7.34ϫ10 -3 s -1 , and therefore
FACS analysis of B7RP-1-Fc binding to ICOS the equilibrium binding constant (K D ) was predicted to be
The B7RP-1-Fc fusion protein was used in FACS analysis to 7.77ϫ10 -9 M (Table 1 ). This is in general agreement with the detect human PBMC that express its receptor, presumably previously described affinities of the CTLA-4 and B7 proteins ICOS. ICOS is expressed on few CD45RA ϩ naive T cells and (19). This system was then applied to the ICOS-Fc and B7RP-a small population of CD45RO ϩ memory T cells (Fig. 2) . A 1-Fc constructs. In all cases, B7RP-1-Fc was immobilized to large majority of T cells express ICOS after stimulation overthe chip surface and different concentrations of ICOS-Fc night with PMA and ionomycin. No binding of B7RP-1-Fc to were injected as an analyte. The kinetic constants from a B cells or monocytes was observed (data not shown). This representative experiment are summarized in Table 1 and expression is consistent with murine studies (15) and with show that B7RP-1 binds to ICOS. The calculated equilibrium ICOS antibody binding data (14). binding constant for each interaction is in the low nanomolar FACS analysis of B7RP-1 expression on APC range, indicating a strong affinity that is consistent with other described T cell interactions. However, differences are Biotinylated ICOS-Fc fusion protein was used to detect B7RP-1 expression on APC. Human PBMC were purified and DC observed in the association and dissociation rates. Interestingly, murine B7RP-1 interacts well with human ICOS; howwere cultured as described in Methods. Specificity of ICOSFc-biotin binding to human monocytes was shown by a ever, neither B7RP-1 nor ICOS interacts with proteins in the CD28 regulated pathway.
competition FACS analysis (Fig. 3) . Pre-incubating the cells with a 10-fold excess of unlabeled ICOS-Fc (Fig. 3A) inhibited the majority of the ICOS-Fc-biotin binding (83%), but preincubating with an excess of unlabeled control Fc construct (DR4-Fc, Fig. 3B ) did not. B7RP-1 is expressed on PB B cells and monocytes, and on PB monocyte-derived DC (Table  2) . TNF-α-treatment enhanced the ICOS-Fc fusion protein binding to B cells (1.7-fold increase in mean ∆MFI, three donors) and monocytes (3.9-fold increase in mean ∆MFI; P Ͻ 0.05, four donors). The increase in the magnitude of the mean ∆MFI of ICOS-Fc binding to TNF-α stimulated B cells, compared to unstimulated B cells, was not statistically significant (P Ͼ 0.05) due to large donor to donor variability; nevertheless, TNF-α consistently enhanced ICOS-Fc binding to B cells with all donors. Statistically relevant results were obtained when B cells (2.2-fold increase in mean ∆MFI; P Ͻ 0.05) and monocytes (3.2-fold increase in mean ∆MFI; P (Fig. 4) . These DC were graph) and IFN-γ (bottom graph) production. B7RP-1-Fc was used CD14 -, CD1a ϩ/-, CD11c hi , CD40 ϩ , MHC class II (HLA-DR) hi , at 5 µg/ml and the anti-CD3 antibodies were used at 0.5 µg/ml. Data CD86 ϩ and CD80 ϩ/-as has been previously described (18).
are representative of results generated with three normal donors.
CD1a ϩ DC (10-50% of total DC generated) were typically 92% B7RP-1 ϩ and CD1a -DC were typically 70% B7RP-1 ϩ . DC cultured with TNF-α had a similar phenotype, except there were fewer CD1a ϩ DC (10-18% of total DC), with slightly 1-expressing CHO cells and B7RP-1-Fc fusion protein in enhanced B7-1 expression (1.3-fold increase in mean ∆MFI, T cell proliferation assays. B7RP-1-Fc demonstrated co-P Ͻ 0.02), and reduced B7RP-1 expression on both CD1a ϩ stimulatory activities that are dependent on anti-CD3 stimulaand CD1a -DC. Therefore, TNF-α treatment increased the tion (Fig. 5A ). In addition, this activity can be specifically expression of B7RP-1 on B cells and monocytes, but inhibited with soluble ICOS-Fc protein (Fig. 5B) . The codecreased the expression of B7RP-1 on DC.
stimulatory effects by the B7RP-1-Fc fusion protein are dose T cell proliferation assays dependent, and simultaneous co-stimulation of both the ICOS and CD28 pathways results in additive effects, suggesting To determine whether the human B7RP-1 protein has costimulatory activity on human T cells, we tested human B7RP-similar, but non-overlapping functions ( Fig. 5C and D) . Similar T cells (14). We found that B7RP-1 ligand stimulation of human T cells generates a pattern of cytokine production similar to that generated with the anti-ICOS mAb F44 or with mouse B7RP-1-Fc, although we found that the B7RP-1-Fc consistently induced less IL-10 than CD28-activating antibodies.
Since the F44 mAb induced more IL-10 than CD28 antibodies (14), it may have greater effects on IL-10 than the natural ligand.
In order to clarify the role of B7RP-1 in immunoregulation, we sought to identify the factors that regulate B7RP-1 expression in human immune cells. Swallow et al. recently demonstrated that TNF-α enhanced murine B7RP-1 mRNA expression in mouse fibroblasts (21). We show that APC maturation-inducing agents (TNF-α and LPS) regulate B7RP-1 expression on APC. Unstimulated PB B cells and monocytes constitutively express B7RP-1, and its expression was further ICOS pathways. Furthermore, we show that B7RP-1 is coexpressed with B7 molecules on human DC, and the simultaneous stimulation of both the CD28 and ICOS pathways has complementary effects on T cell proliferation in vitro. Taken co-stimulatory effects were obtained using CHO cells that express membrane-bound B7RP-1 (Fig. 6) .
together, our data indicate that B7RP-1 is a positive regulating ligand for ICOS-mediated T cell co-stimulation. The possibility Cytokine production remains that, like CTLA-4, ICOS is a negative regulator and B7RP-1 may function via an unknown, positive factor. As with The production of cytokines by human T cells under the above in vitro proliferation conditions was determined by the characterization of CTLA-4 (23,24), conclusive functional data can be obtained by ICOS gene deletion studies in mice. ELISA using cell culture supernatants. We found IFN-γ and IL-10 levels were significantly increased; however, unlike These studies are currently in progress. It is interesting to consider how B7RP-1/ICOS co-stimulation CD28 co-stimulation, IL-2 was only slightly increased at the 72 h timepoint (Fig. 7) . Generally, this is consistent with relates to B7/CD28 co-stimulation. We suggest CD28 signaling may play a dominant role during T cell priming and ICOS previous results using ICOS antibodies; however, the magnitude of the induction of IL-10, relative to anti-CD28 antibody signaling may emphasize effector functions. The temporal expression patterns of CD28 and ICOS are consistent with induction, was variable between donors (data not shown). In addition, a blockade using antibodies to IL-2 inhibited B7RP-this hypothesis. CD28 is constitutively expressed, while ICOS expression requires induction on CD45RA ϩ naive T cells and 1-induced co-stimulation (Fig. 8) . This suggests that, although IL-2 levels were not substantially elevated by B7RP-1 comost CD45RO ϩ memory T cells. The modulation of the expression patterns of B7RP-1 on DC, B cells and monocytes stimulation, the IL-2 that was produced was required for B7RP-1-induced T cell proliferation.
shown here is also consistent with the putative B7RP-1 functions on effector cells. Naive T cells respond optimally to mature DC that express high levels of B7 (25,26) and these Discussion cells appear to express low levels of B7RP-1. On the other hand, effector T cells are adequately stimulated by B cells or We have described the cloning of human B7RP-1 and have demonstrated that it is an authentic ligand for the recently macrophages, which express relatively low levels of B7 and high levels of B7RP-1 (26,27). described T cell co-stimulatory protein, ICOS (14). The establishment of in vitro human T cell assays using the human
The fact that the proteins in the CD28 and ICOS pathways do not interact, i.e. that they are separate receptor-ligand B7RP-1 ligand is essential to identify inhibitors with potential clinical relevance and to determine if the natural human B7RP-pairs, may suggest they have inherent differences in their functions. It is also possible that the CD28 and ICOS pathways 1 ligand functions similarly to mouse B7RP-1 or an ICOS mAb. B7RP-1 co-stimulation of anti-CD3-stimulated human have complementary functions. Our in vitro assays show additive effects when both pathways are stimulated. Further-PB T cells results in dose-dependent proliferation and cytokine production. These results are consistent with our recent report more, while the receptors or ligands of the two pathways are sometimes expressed on the same cells, they are differentially on murine B7RP-1 (15) , which positively regulates splenic T cell growth and cytokine production, and results by Hutloff regulated by TNF-α. Accumulating data indicate that B7 costimulation may be more important to naive T cell priming, et al. that showed positive co-stimulatory function by mAbmediated (F44) ICOS cross-linking on CD3-stimulated human while B7RP-1 co-stimulation may be primarily involved in
